Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

The FDA's approval of Alzheimer's treatment Aduhelm puts physicians in a difficult position: They hold the prescribing power over a drug that most say is unproven. But desperate patients and families may not know or care about the lack of evidence and will want the prescription anyway.

What they're saying: "The public message has to be clear: This is not a cure, and it's not even clear this is going to make substantial changes to someone's disease course," said Sharon Brangman, an Alzheimer's expert and geriatrician at Upstate University Hospital in New York.

By the numbers: Almost 90% of physicians disagree with the FDA's approval of Aduhelm, and roughly 80% said they will not prescribe it, according to a new Medscape survey of doctors.

  • At a minimum, doctors believe the FDA's label for Aduhelm is too broad, and the drug should only be for patients who have mild dementia and who have gotten scans showing they have the sticky brain plaques that the drug removes, according to interviews with doctors.

Yes, but: Patients and their family members have been asking about Aduhelm nonstop since the FDA approval.

  • Brangman says her clinic is fielding visits and calls from 40-60 patients per day, and each patient is asking about the drug.
  • Physicians worry that despite how much they educate people about Aduhelm's unproven benefit, risky side effects, and high price, people will push for the prescription.
  • "My mother-in-law has advanced Alzheimer's. Would I give her this medication? Absolutely not," said Marc Gordon, a neurologist and Alzheimer's researcher at Northwell Health in New York. "But will doctors sometimes feel like they're doing something against their better judgment to appease the wishes of patients and families? Probably."
  • Gordon, who believes the drug's approval will lead to "unrealistic expectations," said one of his colleagues in a private neurology practice got "yelled at by a patient's family because they couldn't get the drug the next day."

The other catch: Physicians and hospitals will have a major financial incentive to prescribe the drug.

  • If Medicare covers Aduhelm, it will fall under Medicare Part B.
  • Medicare adds a 6% markup for all Part B drugs, which has long created concerns that providers are prescribing higher-priced drugs to get higher add-on fees.
  • Aduhelm has a list price of $56,000 per year, which would mean thousands of dollars per patient every year just in Medicare add-on fees.
  • And since hospitals and private equity firms increasingly own neurology clinics, "health systems could see this as a new opportunity to bring in revenue and start advertising their memory care," said Joseph Ross, a Yale University physician and researcher who has criticized Aduhelm's approval.

The bottom line: "[Aduhelm] puts physicians in a much more challenging role of walking patients through what to expect," Ross said.

Go deeper: New Alzheimer's drug is a catastrophe in the making

Go deeper

Mike Allen, author of AM
26 mins ago - Politics & Policy

America's "Friendscape" crisis

New research shows Americans have fewer friends than in the past, and are less likely to have a best friend.

  • Why it matters: At a time of excruciating mental and societal stress, this is another sign we're breaking apart. And the friendship drought could get worse with more people working remotely or hybrid-ly.

Pelosi says it's her "plan" to appoint GOP Rep. Kinzinger to Jan. 6 committee

House Speaker Nancy Pelosi (D-Calif.) said Sunday that it is her "plan" to appoint Rep. Adam Kinzinger (R-Ill.) to the House select committee investigating the deadly Jan 6. Capitol riots.

Why it matters: Pelosi's statement to ABC's "This Week" comes after she rejected two of the five Republican appointments offered by House Minority Leader Kevin McCarthy (R-Calif.).

Updated 4 hours ago - Sports

Olympics dashboard

⛳️: Golfer Bryson DeChambeau will miss Olympics after testing positive for COVID

📺: The Olympic events to watch today

🏊: Athlete spotlight — When to watch swimming star Katie Ledecky

🏀: U.S. Men's basketball suffers first Olympic loss since 2004

🤖: The robot Olympics

🚨: Heat wave brings scorching temperatures to Tokyo Olympics

🎤: Meet the new faces of NBC's Olympics coverage

Go deeper: Full Axios coverage